According to a new research report “Wnt Signaling Pathway Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, Wnt Signaling Pathway Inhibitors therapeutics currently exhibits a proliferating pipeline with 27 therapeutic candidates.
Insights into Wnt Signaling Pathway Inhibitors Pipeline
Wnt signaling pathway plays an important role in embryonic development. The signaling pathway regulates cell-to-cell interaction, accelerates trophoblast development, activates blastocyst, accelerate chorion-allantois fusion and implantation. A wide range of diseases, such as different types of cancer and degenerative diseases can be treated by deregulation of components involved in Wnt/β-catenin signaling pathway. Also, researchers have demonstrated that moderate weakening of Wnt signaling can eliminate its carcinogenic potential. Based on the recent researches, Wnt Signaling Pathway inhibitors have also shown potential in cardiovascular disorders.
Insights into Pipeline Segments
According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; and has less risk of systemic infections. Administration of Wnt Signaling Pathway Inhibitors through oral route has shown promising results in the clinical studies. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.
Positive Clinical Trial Results are Expected to Drive the Advancements in Wnt Signaling Pathway Inhibitors Pipeline
The companies developing Wnt Signaling Pathway inhibitors for the treatment of cancer and degenerative diseases, have shown positive clinical results in the various phases of drug development. For instance, in October 2018, Samumed LLC, announced the topline data from the phase IIb trial SM04690 in knee osteoarthritis, wherein the treatment with SM04690 showed improvement in function, pain, and global scores of patients.
Browse Detailed Report on "Wnt Signaling Pathway Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/wnt-signaling-pathway-inhibitors
Technological Advancements Play a Pivotal Role in the Wnt Signaling Pathway Inhibitors Pipeline Development
It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of Wnt Signaling Pathway inhibitors. These technologies play an important role in the drug development thereby helping the companies develop more specific and effective targeted therapies. For instance, the focus of Samumed's technology platform is on the ability to modulate the Wnt signaling pathway in selected tissues with small molecules. The company has discovered various new biological processes related to the Wnt signaling pathway, identified novel biological targets, and developed small-molecule drugs that modulate Wnt activity. In addition, JW Pharmaceutical CORPORATION is engaged in the development of novel therapeutics using high-throughput screening technology and chemical library. The company specializes in identifying small molecule drugs that modulate signaling pathways involved in cell proliferation and differentiation.
Some of the key players involved in the development of Wnt signaling pathway inhibitors in the late and mid stage include Samumed LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics Inc., Leap Therapeutics Inc., 2X Oncology Inc., Eisai Co. Ltd., and Novartis AG.
Wnt Signaling Pathway Inhibitors Pipeline Analysis
The report comprises of detailed pipeline analysis of Wnt signaling pathway inhibitors, analyzing the emerging therapies and their progress status in different phases of development. Comprehensive insights into the pipeline phase products has been provided with special focus on strategic development activities inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, and patent. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to Wnt signaling pathway inhibitors.